Meta-Analysis of Second Malignant Tumors in Head and Neck Cancer: The Case for an Endoscopic Screening Protocol

Annals of Otology, Rhinology and Laryngology - Tập 101 Số 2 - Trang 105-112 - 1992
Bruce H. Haughey1, Cynthia L. Arfken1, George A. Gates1, Joseph E. Harvey1
1St. Louis, Missouri

Tóm tắt

A meta-analysis was performed on data from the Washington University Department of Otolaryngology Head and Neck Tumor Registry and 24 studies reporting synchronous and metachronous malignancies in head and neck cancer patients. The overall second malignant tumor (second primary) prevalence was 14.2% in 40,287 patients, the majority of tumors being metachronous. Site relationships between index tumors and second primaries revealed significantly high risks along the digestive tract axis or the respiratory tract axis, although lung second primaries were prevalent in all groups. Head and neck second primaries were the largest group, being significantly more common in the oral cavity, oropharynx, and hypopharynx than in the larynx. Oral cavity index tumors showed the highest overall rate of second primary formation. Half of all aerodigestive tract second primaries are detected by 2 years from index tumor presentation, but non-aerodigestive tract tumors are common beyond 5 years. A significantly higher detection rate was proven for the prospective panendoscopy studies. We recommend routine interval endoscopic intervention within 2 years of treatment for optimum detection of second primaries in head and neck cancer patients. Also, a lifetime of clinical surveillance is suggested for aerodigestive tract second neoplasms in oral cavity, oropharynx, and hypopharynx cancer patients and for lung and non-aerodigestive tract neoplasms in larynx cancer patients.

Từ khóa


Tài liệu tham khảo

10.1001/archotol.1984.00800350006003

10.1002/1097-0142(19850915)56:6<1242::AID-CNCR2820560603>3.0.CO;2-Z

10.1177/019459989010300103

10.1016/0360-3016(89)90094-1

10.1001/archotol.1985.00800110067004

10.1001/archotol.1986.03780110048006

Warren S, 1932, Am J Cancer, 51, 1358

Berg JW, 1970, J Natl Cancer Inst, 44, 263

10.1288/00005537-197906000-00015

10.1177/000348947908800620

10.1016/S0196-0709(80)80022-6

10.1177/019459988008800410

10.1177/000348948109000509

10.1177/000348948209100306

10.1288/00005537-198205000-00020

10.1111/j.1365-2273.1983.tb01442.x

10.1017/S002221510009469X

10.1016/0360-3016(84)90233-5

10.1017/S0022215100100313

Lundgren J, 1986, J Otolaryngol, 15, 145

Masaki N, 1987, Jpn J Clin Oncol, 7, 303

10.1016/0360-3016(89)90095-3

10.1288/00005537-198912000-00011

10.1177/019459989010300103

10.1016/0360-3016(88)90275-1

10.1001/archsurg.1985.01390330019003

10.1002/hed.2880120604

10.1288/00005537-198301000-00014

10.1016/S0901-5027(89)80140-7

10.1177/000348948709600601

10.1002/1097-0142(19800815)46:4<758::AID-CNCR2820460420>3.0.CO;2-8

10.1002/1097-0142(19901115)66:10<2068::AID-CNCR2820661005>3.0.CO;2-W

10.14219/jada.archive.1983.0004